Orchid Pharma Ltd
As of 20 Nov 2026, Orchid Pharma is in Stage 3, the topping phase, now in week 5 (since 21 Oct 2026). It closed at ₹960, 13.3% below its 52-week high and above its 200-day average, which is rising. In Health Care, 34.7% of stocks are in Stage 2.
Orchid Pharma Limited, a pharmaceutical company, engages in the development, manufacture, and marketing of active pharmaceutical ingredients, bulk actives, finished dosage formulations, and nutraceuticals in India. More about the company
Pro read
ProORCHPHARMA's uptrend is tiring: 5 weeks into a top. A topping stock either breaks back out or rolls over into a decline, and the next few weeks usually settle which.
Its relative strength is 80 of 99, a leader among NSE stocks over the past year. Pharmaceuticals ranks 7 of 106 industries by the strength of its stocks, among the leaders.
Is ORCHPHARMA early, or has it already run? Pro answers that for every NSE stock, after every close.
ORCHPHARMA among Pharmaceuticals44th of 118 by relative strength
All 118 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | BLISSGVS | Stage 2 · wk 49 | 99 | +4.6% |
| 2 | KPL | Stage 2 · wk 44 | 99 | +20.5% |
| 3 | FREDUN | Stage 2 · wk 33 | 98 | +24.0% |
| 4 | VENUSREM | Stage 3 · wk 10 | 98 | −1.5% |
| 5 | RUBICON | Stage 3 · wk 4 | 98 | +18.7% |
| 6 | SAKAR | Stage 2 · wk 55 | 98 | +13.1% |
| 7 | BAFNAPH | Stage 2 · wk 23 | 98 | +1.9% |
| 8 | INDSWFTLAB | Stage 2 · wk 23 | 98 | −7.4% |
| …44 | ORCHPHARMA | Stage 3 · wk 5 | 80 | +8.3% |
Mutual fund holdings
Held by 14 mutual funds in portfolios to October 2026: 10 active funds and 4 index funds and ETFs.
In October, among active funds: 1 increased.
- UTI Value Fund1.10%
- Tata India Innovation Fund0.98%
- Quant Small Cap Fund0.86%
All 14 funds and what each did in October
Mutual funds holding ORCHPHARMA: the ten largest and the month’s moves →
Orchid Pharma: quick answers
What stage is Orchid Pharma in?
As of 20 Nov 2026, Orchid Pharma (ORCHPHARMA) is in Stage 3, the topping phase. It entered Stage 3 on 21 Oct 2026 and is in week 5. What the four stages mean
Is Orchid Pharma in an uptrend?
Its uptrend has stalled. Orchid Pharma is in Stage 3, the topping phase that follows an advance. It trades 16.5% above its 200-day average, which is rising.
How far is Orchid Pharma from its 52-week high?
Orchid Pharma closed at ₹960 on 20 Nov 2026, 13.3% below its 52-week high of ₹1,107. Its 52-week low is ₹482.
How has Orchid Pharma performed over the past year?
As of 20 Nov 2026, Orchid Pharma is up 20.3% over the past year and up 26.5% so far in 2026.
Which sector and industry is Orchid Pharma in?
Orchid Pharma is in the Pharmaceuticals industry, part of the Health Care sector. 61 stocks in Health Care are in Stage 2, 34.7% of the sector. See the Stage 2 stocks in Pharmaceuticals
About this companyHealth Care· Pharmaceuticals
Orchid Pharma Limited, a pharmaceutical company, engages in the development, manufacture, and marketing of active pharmaceutical ingredients, bulk actives, finished dosage formulations, and nutraceuticals in India. Its active pharmaceutical ingredients product portfolio includes oral cephalosporins, injectable cephalosporins; human and veterinary products; and antibiotics, including betalactam, macrolide, fluoroquinolone, and imidazole. The company also exports its products to approximately 40 countries internationally. The company was formerly known as Orchid Chemicals & Pharmaceuticals Limited and changed its name to Orchid Pharma Limited in October 2015. Orchid Pharma Limited was incorporated in 1992 and is headquartered in Chennai, India. Orchid Pharma Limited operates as a subsidiary of Dhanuka Laboratories Limited.
Visit company website →All analytics based on EOD data. Data as of 2026-11-20. Past data patterns are not indicative of future results. This page is a data analytics tool only.